<DOC>
	<DOCNO>NCT00742417</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety plasma exchange 5 % albumin beta-amyloid peptide clearance cerebrospinal fluid , effect patient mild-moderate Alzheimer 's disease .</brief_summary>
	<brief_title>Efficacy Safety Plasma Exchange With 5 % Albumin Beta-amyloid Peptide Clearance Cerebral Spinal Fluid</brief_title>
	<detailed_description>A phase II study conduct primarily determine whether plasma exchange 5 % human albumin able modify concentration beta-amyloid peptide cerebrospinal fluid ( CSF ) patient AD . - There two week screen randomization group ( treatment control ) . - The subject randomize 1:1 proportion . After screen randomization , treatment proceed follow : - three week intensive treatment two plasma exchange per week - follow month half maintenance treatment one weekly plasma exchange , - finally , three month treatment one plasma exchange every two week . The control group follow program , except plasma exchange . After treatment period end , subject followed-up 6-month period time . The trial comprise global multicenter ( Spain US ) , blind , randomize , control design . The trial key coordination base Spain Dr. Boada ( see Study Officials/Investigators ) main study official .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>A diagnosis AD ( National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association [ NINCDSADRDA ] criterion ) , Minimental Status Examination ( MMSE ) score ≥18 ≤26 . Current stable treatment acetylcholine esterase inhibitor ( AChEIs ) previous three month . A stable care taker must available , must attend patient study visit . The patient close relative legal representative must read patient information sheet , agree participation trial , sign inform consent document ( patient personally close relative/legal representative ) . The patient must able follow study protocol , receive treatment establish time period , continue followup interval . A brain Computed Axial Tomography ( CAT ) Magnetic Resonance Imaging ( MRI ) study , obtain 12 month prior recruitment , show absence cerebrovascular disease , must available . Any contraindication plasma exchange due behavioral disorder abnormal coagulation parameter A history frequent adverse reaction ( serious otherwise ) blood product . Hypersensitivity albumin allergy component Albutein 5 % Human Albumin . Plasma creatinine &gt; 2 mg/dL . Uncontrolled high blood pressure . Liver cirrhosis liver problem alanine aminotransferase ( GPT ) &gt; 2.5 x upper limit normal ( ULN ) , bilirubin &gt; 2 mg/dL . Heart diseases , include antecedent coronary disease heart failure . Difficult venous access preclude plasma exchange . Participation clinical trial , reception investigational drug three month prior start study . Any condition complicate adherence study protocol ( illness less one year expect survival , toxic habit , etc. ) . Pregnant nursing woman woman use effective contraceptive method least one month plasma exchange . Fewer six year education . Prior behavioral disorder require pharmacological treatment , include insomnia .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Alzheimer 's</keyword>
	<keyword>Dementia</keyword>
	<keyword>Senile</keyword>
	<keyword>Loss cognitive ability</keyword>
	<keyword>Old age</keyword>
	<keyword>Elderly</keyword>
	<keyword>Aging</keyword>
	<keyword>Albumin</keyword>
	<keyword>Caregiver</keyword>
	<keyword>amyloid</keyword>
	<keyword>beta amyloid</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Brain Disease</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Plasma Exchange</keyword>
</DOC>